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L E T T E R  T O  T H E  E D I T O R
Long- term disruption of cytokine signalling networks is evident 
in patients who required hospitalization for SARS- CoV- 2 
infection
To the Editor,
The current pandemic caused by the SARS- CoV- 2 virus has so far in-
fected more than 130 million people worldwide, resulting in approxi-
mately 3 million deaths. While the current clinical and public health 
priorities are designed to limit severe acute and fatal episodes of the 
disease, and to quickly roll out vaccines to the general population, it 
has become apparent that there may also be significant detrimental 
long- term effects following SARS- CoV- 2 infection that impact daily 
functioning and quality of life.1 The mechanisms underpinning the 
post- acute sequelae of SARS- CoV- 2 infection's long- lasting symp-
toms can include direct effects of the infection (eg endothelial dam-
age, lung fibrosis) or indirect effects associated with changes in the 
microbiome or abnormalities in inflammatory and immune signalling 
pathways stimulated by the infection.2,3
In order to examine the potential long- term immune changes that 
occur following elimination of the primary infection, we examined 
the levels of 52 cytokines and growth factors (using MSD multiplex 
kits) in the serum of patients who attended follow- up post- COVID 
infection clinics at Cork University Hospital, Cork, Ireland (the 
Clinical Research Ethics Committee of the Cork Teaching Hospitals 
approved this study and all patients provided informed consent). 
We choose cytokines that are representative of a wide range of 
different types of immune responses and immune processes in-
cluding Th1, Th2, Th9, Th17, Tregs, acute phase responses, vascular 
remodelling and angiogenesis, growth factors, adhesion molecules, 
chemokines and innate proinflammatory responses. All patients 
had been hospitalized for PCR- proven SARS- CoV- 2 infection (me-
dian in- patient stay of 5.5 days, range 1 day to 24 days) during the 
first wave of the pandemic in Ireland (March- May 2020). Thirty- 
eight serum samples were obtained from twenty- four patients (me-
dian age 53.5 years, 11 female) at 3– 9 months following hospital 
discharge (two samples at least 1 month apart were obtained from 
14 patients, while 1 sample only was obtained from 10 patients). 
Clinical severity ranged from mild to critical during hospitalization, 
and the most common symptoms at follow- up clinics were fatigue 
and/or dyspnoea (Table S1). Sera obtained prior to the pandemic 
from twenty- nine healthy volunteers (median age 43.2 years, 14 
female) were analysed in parallel.
Of the 52 analytes measured, 19 were significantly elevated in 
post- COVID patient sera compared to healthy controls (Table S2). 
These 19 mediators are illustrated as dot plots in Figures 1 and 
2. One group of mediators, C- reactive protein (CRP), serum am-
yloid A (SAA), interleukin- 1 receptor antagonist (IL- 1RA), IL- 6, 
IL- 8, IL- 15, IL- 16, monocyte chemotactic protein (MCP)- 1 and 
MCP- 4, can be broadly categorized as being associated with 
ongoing inflammatory responses (Figure 1A).4 These mediators 
remained as elevated in samples taken 6– 9 months following 
hospital discharge as those levels observed 3– 6 months follow-
ing discharge (Table S2). A second group of mediators, vascular 
endothelial growth factor (VEGF- A), soluble tyrosine- protein ki-
nase receptor Tie- 2 (Tie- 2), soluble intercellular adhesion mole-
cule (ICAM- 1) and basic fibroblast growth factor (bFGF), can be 
generally associated with endothelial dysfunction, remodelling 
and angiogenesis (Figure 1B).5 The remaining elevated mediators 
are associated with patterns of lymphocyte polarization. Elevated 
IL- 4, macrophage- derived chemokine (MDC) and thymic stro-
mal lymphopoietin (TSLP) sera levels indicate activation of TH2 
responses (Figure 2A), while IL- 17A, macrophage inflammatory 
protein (MIP)- 3α and IL- 12/23p40 indicate ongoing TH17 activity 
(Figure 2B). Other indicators of TH2- associated activities are just 
outside statistical significance (IL- 5, p = .112; Table S2). While TH1 
responses are well described to be upregulated during acute in-
fection,6 the levels of these mediators (eg IFN- γ, IP- 10) decrease 
following elimination of the virus and are at control levels in our 
cohort of post- COVID patients (Table S2).
Our data suggest that there are long- term immunological con-
sequences following SARS- CoV- 2 infection, at least in those who 
had acute symptoms severe enough to require hospitalization 
(summarized in Figure S1). While the relatively low number of 
patients included in our study at this stage does not allow us to 
perform subgroup analysis, it is possible that these immune me-
diators may associate with clinically meaningful disease variables 
and ultimately may be of therapeutic value, if findings are repli-
cated in future studies. Of particular interest is the elevation in 
TH2- associated mediators. Could this response be a component of 
the mucosal repair mechanisms that occur following viral damage, 
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F I G U R E  1  Proinflammatory and endothelial mediators in post- COVID patients. Proinflammatory mediators (A) and angiogenesis- 
associated factors (B) are elevated in sera from patients 3– 9 months post- COVID hospital discharge compared to levels in sera from healthy 
controls. Results are illustrated on a log scale, and the mean ± standard error is indicated for each group. Depending on the data distribution, 
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or does this indicate new TH2- associated pathological immune ac-
tivity that might underpin an increased risk of developing allergy or 
asthma? Clearly, the potential immune mechanisms underpinning 
the emerging post- COVID clinical entities will become increasingly 
more important to understand as the healthcare systems adapt to 
caring for large numbers of COVID- 19 survivors during the coming 
months and years.
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F I G U R E  2  TH2 and TH17 cytokines in post- COVID patients. Sera from patients 3– 9 months post- COVID hospital discharge are 
significantly different compared to healthy controls for TH2 cytokines (A) and TH17 cytokines (B). Results are illustrated on a log scale, and 
the mean ± standard error is indicated for each group. Depending on the data distribution, unpaired t- tests or Mann- Whitney tests were 
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